Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2008

View Archived Issues

Genzyme reviews quarterly developments

Novel anti-HIV agents disclosed in recent patent literature

Recent Targacept and AstraZeneca patents disclose new agents for neurological disorders

Novel therapeutics for gastrointestinal disorders reported in recent RaQualia patent

Vertex reviews Q3 highlights

OSI presents OXA-01 at EORTC-NCI-AACR Symposium

PDGFRalpha antibody MEDI-575 characterized in vitro, in vivo

Phase II dose of anticancer agent CS-7017 selected

SGN-70 investigated for potential in autoimmune disorders

Novel tubulin inhibitor ALB-109564 active in xenograft studies

Halozyme initiates phase II trial of insulin with rHuPH20 in type 1 diabetes

Avineuro advances two potent small molecules for AD into clinical development

Xamiol launched in Europe for scalp psoriasis

Genzyme and Osiris sign strategic alliance for Prochymal and Chondrogen stem cell products

Acusphere and Cephalon sign exclusive worldwide license agreement for AI-525

MonoSol and Midatech sign agreement to develop therapeutic nanoparticles in thin film

Biotec initiates enrollment in second phase III study of SBG for diabetic ulcers

Posters detail discovery, preclinical investigation of Met kinase inhibitor BMS-777607

Antibacterial activity of new fluoroquinolone JNJ-Q2 described

First-in-human study of HIV protease inhibitor SPI-256 completed

HemaQuest receives orphan drug status for HQK-1001 for hemoglobin disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...